- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Cardiovascular Psychiatry and Neurology
Volume 2009 (2009), Article ID 849519, 5 pages
Putative Role of MicroRNA-Regulated Pathways in Comorbid Neurological and Cardiovascular Disorders
1Centre de Recherche du CHUQ (CHUL), Axe Neurosciences, Canada
2Département de Biologie Médicale, Université Laval, Laval, Canada QC G1k 7P4
Received 27 May 2009; Revised 26 June 2009; Accepted 2 July 2009
Academic Editor: Hari Manev
Copyright © 2009 Sébastien S. Hébert. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. The conserved noncoding microRNAs (miRNAs) that function to regulate gene expression are essential for the development and function of the brain and heart. Changes in miRNA expression profiles are associated with an increased risk for developing neurodegenerative disorders as well as heart failure. Here, the hypothesis of how miRNA-regulated pathways could contribute to comorbid neurological and cardiovascular disorders will be discussed. Presentation. Changes in miRNA expression occurring in the brain and heart could have an impact on coexisting neurological and cardiovascular characteristics by (1) modulating organ function, (2) accentuating cellular stress, and (3) impinging on neuronal and/or heart cell survival. Testing. Evaluation of miRNA expression profiles in the brain and heart tissues from individuals with comorbid neurodegenerative and cardiovascular disorders will be of great importance and relevance. Implications. Careful experimental design will shed light to the deeper understanding of the molecular mechanisms tying up those different but yet somehow connected diseases.
In recent years, increasing evidence suggests that genetic and epigenetic factors could be involved in disease comorbidity [1–3]. On this line of thought, Lee et al. have identified a common network of genes (and metabolic pathways) that was altered in Alzheimer’s disease (AD) coinciding with myocardial infarction (MI) . Indeed, increased activity of ACE and APOE genes, both involved in lipid metabolism, was significantly associated to the coexistence of these disorders. Given the central role of the genome and proteome in biology and pathobiology, it is safe to predict that misregulation of specific gene expression networks could influence disease state and in some cases comorbidity.
Following the discovery of microRNAs (miRNAs) in C. elegans more than a decade ago , research has majorly evolved in order to gain insight of how the miRNA gene network can have an impact on health and disease in humans. Studies in animal models demonstrate that miRNA genes are essential for life [5, 6], whereas changes in miRNA expression profiles in humans are found in several diseases, such as cancer  as well as neurological and cardiovascular disorders (see below).
The miRNA gene family comprises a class of highly conserved small ( nt) nonprotein-coding RNAs that function in the cell to regulate gene expression at the posttranscriptional level . Like protein-coding genes, miRNAs are embedded in the genome and generated by a multistep process ( and references therein). The fully processed mature miRNA molecule functions as part of the RNA-induced silencing complex (RISC) and affects gene expression. This is achieved by binding to the UTR of target messenger RNAs (mRNAs), leading to their translational repression or degradation. Individual or families of miRNAs can target up to several hundred mRNAs, thus controlling complex gene expression pathways and biological systems .
The role of miRNAs, in accordance with most biological systems, has been best studied in development. Initial studies inactivating Dicer, a type III RNase involved in miRNA maturation (and therefore function), demonstrate that miRNAs are essential for life . Tissue-specific deletion of Dicer (and subsequently mature miRNAs) causes abnormal brain and heart development in both Zebrafish and mouse [11–14]. Cell-specific functional roles for miRNAs in these organs are also emerging. In detail, the brain-specific miRNA miR-134 is involved in dendritic spine formation as well as in synaptic plasticity , while miR-124  and miR-132  are implicated in neurite outgrowth. In addition, muscle-enriched miR-1 and miR-133 seem to control heart muscle growth and differentiation [18, 19] and recently shown to regulate muscle gene expression and influence sarcomere assembly .
2. Presentation of the Hypothesis
Taking into account the growing evidence that miRNAs are key regulators of gene expression and necessary for the function and maintenance of all major biological systems, it is reasonable to speculate that loss of the fine-tuning of this network could be relevant for the development of comorbid diseases. One would therefore anticipate that miRNA dysfunction occurs concomitantly (or in some cases consecutively) in the brain and heart. Obviously, nonautonomous effects should not be ruled out, since they could indirectly lead to changes in miRNA expression and function.
Out of the known 706 human (547 mouse) miRNAs (http://microrna.sanger.ac.uk/), an abundant and particularly diverse group is expressed in the mammalian brain and heart [21–25]. Several of these miRNAs are coexpressed in both tissues (e.g., miR-29, let-7, miR-21, miR-103, miR-106, miR-17-5p) at various relative levels of expression [22, 26–28]. Interestingly, a study by Kuhn et al. showed that a subset of chromosome 21-derived miRNAs are overexpressed in both the brain and heart tissues of down syndrome patients, thus providing genetic proof-of-concept for the possibility that specific miRNAs can be coregulated in these organs . It is noteworthy that despite the fact that certain miRNAs are likely more involved in tissue development (e.g., miR-106, miR-17-5p) , the expressions of some are specifically altered (either up- or downregulated) in disease or disease-simulated conditions in mouse models and/or in humans. Recent studies have indeed documented changes in the levels of specific miRNAs in several major neurodegenerative disorders including AD [27, 31], Huntington’s disease , and Parkinson’s disease . Alterations in miRNA levels have been shown as well in various heart pathologies including arrhythmia, cardiac fibrosis, angiogenesis, and cardiac hypertrophy (reviewed in [26, 34, 35]). Whether all the reported changes in miRNA expression are involved in respective diseases is doubtful (see below) but remains to be explored.
Given recent findings, the hypothesis that specific variations in miRNA expression could play a significant role in comorbid neurological and cardiovascular pathologies is attractive. Alterations of a single miRNA could have profound effects on hundreds of target genes [36, 37], thus possibly implicating multiple biological pathways. However, not all reported changes in miRNA expression would necessarily be relevant to disease progression. Indeed, only a few miRNAs could exert their regulatory function directly or indirectly on disease-related genes, such as ACE and APOE.
Downregulation of miR-29 in AD brain as well as in MI (commonly known as heart attack) is an appealing example of how a specific miRNA (or miRNA family) network could be involved in simultaneous existence of neurological and cardiovascular pathological features. In vitro and in vivo studies performed in the mouse heart have shown that miR-29 (expressed mainly in cardiac fibroblasts) could regulate various collagens and other ECM proteins involved in cardiac remodeling after MI . In the brain, it is suggested that miR-29 (expressed in both neurons and glia) could contribute to the production of toxic amyloid- peptides by regulating BACE1/-secretase . Other studies have shown that accumulation of amyloid- peptides causes degeneration of cells in the walls of blood vessels, affects vasoactivity, and improves proteolytic mechanisms, such as fibrinolysis, anticoagulation, and degradation of the ECM . Of notice, changes in the ECM are linked to neurodegeneration  and may play a role in AD pathology , whereas it is suggested that collagen levels could modulate amyloid- peptide toxicity in neurons . Thus, the combined action of miR-29 downregulation in the brain and heart could contribute to a detrimental feedback loop between toxic amyloid- production, changes in the ECM, increased cellular stress, and ultimately cell dysfunction and death. In this way, the collective effects of miR-29 downregulation in the brain and heart could significantly increase the risk for MI in AD patients and perhaps be involved in other comorbid neurological and cardiovascular disorders (such as AD and congestive heart failure). It should be noticed that the physiological role(s) of miR-29, as with most miRNAs, remains unknown. Nonetheless, it is safe to predict that changes in (single or numerous) miRNA-regulated pathways may have multiple effects on numerous cellular and biological pathways involved in neurological and cardiovascular physiology and pathophysiology, including apoptosis, lipid metabolism, and oxidative stress.
3. Testing the Hypothesis
Simple studies can be performed to evaluate whether a link between miRNA misexpression and neurological and cardiovascular comorbidity exists. The first step would be to analyze global miRNA expression profiles from total RNA isolated from the brain and heart tissues from (the same) individuals with coinciding characteristics of neurodegenerative and cardiovascular disorders. Several miRNA gene platforms (arrays) are commercially available. In this way, it would be possible to map the individual (i.e., brain- or heart-specific) and shared (i.e., both organs) changes in miRNA expression. Thus, heart and brain tissue banks for research on cooccurring cardiovascular and neurological/psychiatric disorders could be easily used for miRNA studies. Subsequent steps would be focused on the identification of miRNA target genes and pathways, ideally previously associated with (respective or shared) disease(s). Several bioinformatics logarithms for miRNA prediction sites in UTR of genes are freely available online (Pictar, miRANDA, TargetScan, etc.). Functional validation of miRNA target genes in the physiological and pathological contexts may be guided through current literature (e.g., see ).
“What causes changes in miRNA expression?” Unfortunately, the underlying mechanisms of the ways and reasons miRNAs become deregulated in disease (and specifically in comorbid disease) remain largely unknown. It is possible that accumulating genetic, cellular, or environmental insults, for instance, during ageing, could affect miRNA gene expression. Some of these effects are perhaps governed themselves by transcription and/or cellular factors, since miRNAs have regulatory promoter regions and are transcribed mainly by RNA polymerase II [43, 44]. An elegant study by Wang et al. showed that, in myoblasts, the miR-29 promoter (and more particularly the miR-29b-2/miR-29c cluster) is regulated by the transcription factors NFκB and YY1 . During myogenesis, NFκB and YY1 downregulation causes derepression of miR-29 that, in turn, accelerates differentiation by targeting its repressor YY1. Whether this complex regulatory feedback loop between miR-29, NFκB, and YY1 exists in neurons remains to be explored. Interestingly, both NFκB and YY1 have been involved in BACE1 regulation [46, 47], and an increase in YY1 expression was observed in human heart failure . It remains therefore an interesting hypothesis that changes in NFκB and/or YY1 may contribute, at least in part, to abnormal miR-29 expression in both the heart and brain. It has been shown already that decreased miR-29 correlates with increased BACE1 in AD brain . Whether a similar correlation exists between NFκB/YY1 and BACE1 (and perhaps ECM proteins) in these cases needs to be tested. On this line of thought, it would be interesting to see if these elements are affected in the heart of these individuals, or others, suffering from various heart conditions. It is worth mentioning that NFκB seems also to be involved in the regulation of miR-146a expression and could play a role in the inflammation response in AD brain .
Secondary (downstream) effects should also not be ignored, as comorbidity may result from a primary disease. This latter hypothesis could be tested in disease-prone animal models, where, for example, excessive soluble amyloid- peptides produced in the brain of transgenic AD mouse models could induce or modulate miRNA expression in the heart.
4. Implications of the Hypothesis
These results could lead to the identification of common miRNAs and target genes/pathways involved in cooccurring neurological and cardiovascular disorders. The use of RNA interference and miRNA oligonucleotides into clinic could help alleviate the risk for heart failure in patients suffering from AD and possibly other neurodegenerative disorders. Concretely, miR-29 mimics can be used to reduce cardiac fibrosis, thus providing an alternative method of maintaining physiological levels of critical target genes of miR-29. Cardiac fibrosis results in stiffening of the heart, diminished contractility, and abnormalities in cardiac conductance. A beneficial effect of miR-29 mimics on BACE1 and amyloid- levels in the brain (and vascular system) is equally envisaged. Reversing one or both of these processes could therefore represent an important therapeutic target of MI management and neurodegeneration. However, a word of caution is needed especially with regard to unwanted off-target effects and the multiplicity of miRNA targets. Thus, many optimization efforts will be required before miRNAs can be used into clinic.
5. Competing Interests
None is declared.
List of Abbreviations
|BACE1:||Beta-site APP cleaving enzyme|
|ACE:||Angiotensin I converting enzyme|
The author like to thank Aikaterini S. Papadopoulou for critical reading of this article. This work was supported by the NSERC Individual Discovery 092850 Grant.
- D. S. Lee, J. Park, K. A. Kay, N. A. Christakis, Z. N. Oltvai, and A. L. Barabasi, “The implications of human metabolic network topology for disease comorbidity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 29, pp. 9880–9885, 2008.
- J. Park, D. S. Lee, N. A. Christakis, and A. L. Barabasi, “The impact of cellular networks on disease comorbidity,” Molecular Systems Biology, vol. 5, article 262, 2009.
- R. C. McEachin, B. J. Keller, E. F. Saunders, and M. G. McInnis, “Modeling gene-by-environment interaction in comorbid depression with alcohol use disorders via an integrated bioinformatics approach,” BioData Mining, vol. 1, p. 2, 2008.
- R. C. Lee, R. L. Feinbaum, and V. Ambros, “The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14,” Cell, vol. 75, no. 5, pp. 843–854, 1993.
- A. E. Williams, “Functional aspects of animal microRNAs,” Cellular and Molecular Life Sciences, vol. 65, no. 4, pp. 545–562, 2008.
- V. Ambros, “The functions of animal microRNAs,” Nature, vol. 431, no. 7006, pp. 350–355, 2004.
- Y. S. Lee and A. Dutta, “MicroRNAs in cancer,” Annual Review of Pathology.
- S. S. Hebert and B. De Strooper, “Alterations of the microRNA network cause neurodegenerative disease,” Trends in Neurosciences, vol. 32, no. 4, pp. 199–206, 2009.
- O. Hobert, “Gene regulation by transcription factors and microRNAs,” Science, vol. 319, no. 5871, pp. 1785–1786, 2008.
- E. Bernstein, S. Y. Kim, M. A. Carmell, et al., “Dicer is essential for mouse development,” Nature Genetics, vol. 35, no. 3, pp. 215–217, 2003.
- A. J. Giraldez, R. M. Cinalli, M. E. Glasner, et al., “MicroRNAs regulate brain morphogenesis in zebrafish,” Science, vol. 308, no. 5723, pp. 833–838, 2005.
- T. H. Davis, T. L. Cuellar, S. M. Koch, et al., “Conditional loss of dicer disrupts cellular and tissue morphogenesis in the cortex and hippocampus,” Journal of Neuroscience, vol. 28, no. 17, pp. 4322–4330, 2008.
- J. F. Chen, E. P. Murchison, R. Tang, et al., “Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 6, pp. 2111–2116, 2008.
- P. A. da Costa Martins, M. Bourajjaj, M. Gladka, et al., “Conditional Dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling,” Circulation, vol. 118, no. 15, pp. 1567–1576, 2008.
- G. M. Schratt, F. Tuebing, E. A. Nigh, et al., “A brain-specific microRNA regulates dendritic spine development,” Nature, vol. 439, no. 7074, pp. 283–289, 2006.
- J. Y. Yu, K. H. Chung, M. Deo, R. C. Thompson, and D. L. Turner, “MicroRNA miR-124 regulates neurite outgrowth during neuronal differentiation,” Experimental Cell Research, vol. 314, no. 14, pp. 2618–2633, 2008.
- N. Vo, M. E. Klein, O. Varlamova, et al., “A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 45, pp. 16426–16431, 2005.
- N. Liu, S. Bezprozvannaya, A. H. Williams, et al., “microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart,” Genes and Development, vol. 22, no. 23, pp. 3242–3254, 2008.
- J. F. Chen, E. M. Mandel, J. M. Thomson, et al., “The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation,” Nature Genetics, vol. 38, no. 2, pp. 228–233, 2006.
- Y. Mishima, C. Abreu-Goodger, A. A. Staton, et al., “Zebrafish miR-1 and miR-133 shape muscle gene expression and regulate sarcomeric actin organization,” Genes and Development, vol. 23, no. 5, pp. 619–632, 2009.
- E. A. Miska, E. Alvarez-Saavedra, M. Townsend, et al., “Microarray analysis of microRNA expression in the developing mammalian brain,” Genome Biology, vol. 5, no. 9, article R68, 2004.
- L. F. Sempere, S. Freemantle, I. Pitha-Rowe, E. Moss, E. Dmitrovsky, and V. Ambros, “Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation,” Genome Biology, vol. 5, no. 3, article R13, 2004.
- O. Barad, E. Meiri, A. Avniel, et al., “MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues,” Genome Research, vol. 14, no. 12, pp. 2486–2494, 2004.
- H. Hohjoh and T. Fukushima, “Marked change in microRNA expression during neuronal differentiation of human teratocarcinoma NTera2D1 and mouse embryonal carcinoma P19 cells,” Biochemical and Biophysical Research Communications, vol. 362, no. 2, pp. 360–367, 2007.
- M. Kapsimali, W. P. Kloosterman, E. de Bruijn, F. Rosa, R. H. A. Plasterk, and S. W. Wilson, “MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system,” Genome Biology, vol. 8, no. 8, article R173, 2007.
- T. Thum, D. Catalucci, and J. Bauersachs, “MicroRNAs: novel regulators in cardiac development and disease,” Cardiovascular Research, vol. 79, no. 4, pp. 562–570, 2008.
- W. X. Wang, B. W. Rajeev, A. J. Stromberg, et al., “The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1,” The Journal of Neuroscience, vol. 28, pp. 1213–1223, 2008.
- X. Cao, G. Yeo, A. R. Muotri, T. Kuwabara, and F. H. Gage, “Noncoding RNAs in the mammalian central nervous system,” Annual Review of Neuroscience, vol. 29, pp. 77–103, 2006.
- D. E. Kuhn, G. J. Nuovo, M. M. Martin, et al., “Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts,” Biochemical and Biophysical Research Communications, vol. 370, no. 3, pp. 473–477, 2008.
- J. T. Mendell, “miRiad roles for the miR-17-92 cluster in development and disease,” Cell, vol. 133, no. 2, pp. 217–222, 2008.
- S. S. Hébert, K. Horré, L. Nicolaï, et al., “Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/-secretase expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 17, pp. 6415–6420, 2008.
- A. N. Packer, Y. Xing, S. Q. Harper, L. Jones, and B. L. Davidson, “The bifunctional microRNA miR-9/miR-9∗ regulates REST and CoREST and is downregulated in Huntington's disease,” Journal of Neuroscience, vol. 28, no. 53, pp. 14341–14346, 2008.
- J. Kim, K. Inoue, J. Ishii, et al., “A microRNA feedback circuit in midbrain dopamine neurons,” Science, vol. 317, no. 5842, pp. 1220–1224, 2007.
- P. K. Mishra, N. Tyagi, M. Kumar, and S. C. Tyagi, “MicroRNAs as a therapeutic target for cardiovascular diseases,” Journal of Cellular and Molecular Medicine, vol. 13, no. 4, pp. 778–789, 2009.
- A. H. Williams, N. Liu, E. van Rooij, and E. N. Olson, “MicroRNA control of muscle development and disease,” Current Opinion in Cell Biology, vol. 21, no. 3, pp. 461–469, 2009.
- D. Baek, J. Villen, C. Shin, F. D. Camargo, S. P. Gygi, and D. P. Bartel, “The impact of microRNAs on protein output,” Nature, vol. 455, no. 7209, pp. 64–71, 2008.
- M. Selbach, B. Schwanhausser, N. Thierfelder, Z. Fang, R. Khanin, and N. Rajewsky, “Widespread changes in protein synthesis induced by microRNAs,” Nature, vol. 455, no. 7209, pp. 58–63, 2008.
- E. Van Rooij, L. B. Sutherland, J. E. Thatcher, et al., “Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 13027–13032, 2008.
- M. O. McCarron and J. A. R. Nicoll, “Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage,” Lancet Neurology, vol. 3, no. 8, pp. 484–492, 2004.
- A. J. Turner and N. N. Nalivaeva, “New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection,” International Review of Neurobiology, vol. 82, pp. 113–135, 2007.
- C. Bellucci, C. Lilli, T. Baroni, et al., “Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease,” Molecular Medicine, vol. 13, no. 9-10, pp. 542–550, 2007.
- J. S. Cheng, D. B. Dubal, D. H. Kim, et al., “Collagen VI protects neurons against Abeta toxicity,” Nature Neuroscience, vol. 12, pp. 119–121, 2009.
- M. Lagos-Quintana, R. Rauhut, W. Lendeckel, and T. Tuschl, “Identification of novel genes coding for small expressed RNAs,” Science, vol. 294, no. 5543, pp. 853–858, 2001.
- Y. Lee, M. Kim, J. Han, et al., “MicroRNA genes are transcribed by RNA polymerase II,” EMBO Journal, vol. 23, no. 20, pp. 4051–4060, 2004.
- H. Wang, R. Garzon, H. Sun, et al., “NF-kappaBYY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma,” Cancer Cell, vol. 14, pp. 369–381, 2008.
- K. Nowak, C. Lange-Dohna, U. Zeitschel, et al., “The transcription factor Yin Yang 1 is an activator of BACE1 expression,” Journal of Neurochemistry, vol. 96, no. 6, pp. 1696–1707, 2006.
- V. Buggia-Prevot, J. Sevalle, S. Rossner, and F. Checler, “NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42,” Journal of Biological Chemistry, vol. 283, pp. 10037–10047, 2008.
- C. C. Sucharov, P. Mariner, C Long, M. Bristow, and L. Leinwand, “Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter,” Journal of Biological Chemistry, vol. 278, pp. 31233–31239, 2003.
- W. J. Lukiw, Y. Zhao, and J. G. Cui, “An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells,” Journal of Biological Chemistry, vol. 283, pp. 31315–31322, 2008.